Navigation Links
Watson Files FDA Application for Generic Rozerem(R)
Date:12/4/2009

ed on Urology and Women's Health. Watson has operations in over 20 countries including many of the world's established and growing international markets.

For press release and other company information, visit Watson Pharmaceuticals' Web site at http://www.watson.com.

Forward-Looking Statement

Statements contained in this press release that refer to Watson's estimated or anticipated future results or other non-historical facts are forward-looking statements that reflect Watson's current perspective of existing trends and information as of the date of this release. For instance, any statements in this press release concerning prospects related to Watson's product introductions and anticipated financial performance are forward-looking statements. It is important to note that Watson's goals and expectations are not predictions of actual performance. Watson's performance, at times, will differ from its goals and expectations. Actual results may differ materially from Watson's current expectations depending upon a number of factors affecting Watson's business. These factors include, among others, the inherent uncertainty associated with financial projections; the impact of competitive products and pricing; the difficulty of predicting the timing or outcome of litigation; the timing and success of product launches; the difficulty of predicting the timing or outcome of product development efforts and FDA or other regulatory agency approvals or actions; market acceptance of and continued demand for Watson's products; difficulties or delays in manufacturing; the availability and pricing of third party sourced products and materials; successful compliance with FDA and other governmental regulations applicable to Watson's and its third party manufacturers' facilities, products and/or businesses; and such other risks and uncertainties detailed in Watson's periodic public filings wi
'/>"/>

SOURCE Watson Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Watson to Present at Credit Suisse Healthcare Conference
2. Watson and Barr Settle Lawsuit Over Oxytrol(R)
3. Watson Announces United States Availability of RAPAFLO(TM) (silodosin), a Novel New Treatment in Benign Prostatic Hyperplasia (BPH)
4. Watson Announces Positive Data for Its New Investigational Products for Benign Prostatic Hyperplasia and Overactive Bladder
5. Watson Announces Silodosin NDA Accepted for Filing by FDA for the Treatment of Benign Prostatic Hyperplasia
6. Watson Announces Positive Results From Its Pivotal Study of Oxybutynin Topical Gel for the Treatment of Overactive Bladder
7. Watson Launches Generic Biaxin(R) XL
8. Cardium Files FDA 510(k) Application for U.S. Marketing Clearance of ExcellagenXL(TM) Topical Gel and ExcellagenFX(TM) Flowable Collagen Protein-Based Matrix for Diabetic, Pressure and Venous Ulcers and Other Dermal Wounds
9. Cephalon Files Patent Infringement Lawsuit Against Teva Pharmaceuticals
10. Endologix Files Motion to Discontinue Court Proceedings Related to Alleged Patent Infringement
11. Vermillion Files Plan of Reorganization
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/4/2015)... WORCESTER, Mass. and TORONTO ... ( www.generex.com ) (OTCQB:GNBT) today announced that it intends ... securities it receives upon completion of a definitive licensing ... to Smoofi, Inc. ( www.smoofi.com ) (OTCQB:SMFI). ... a non-binding letter of intent in respect of the ...
(Date:5/4/2015)... TAIPEI , May 4, 2015 ... partner, Merrimack Pharmaceuticals, Inc. (NASDAQ: MACK ) ... BAX ) jointly announced that Baxter has ... European Medicines Agency (EMA) for MM-398 (irinotecan liposome ... metastatic adenocarcinoma of the pancreas who have been ...
(Date:5/4/2015)... -- Bayer HealthCare (Bayer) has entered into an exclusive ... ) on ISIS-FXI Rx, an antisense investigational drug ... the agreement Bayer will further develop and commercialize ISIS-FXI ... As part of the clinical development program, Bayer plans ... in an appropriate patient community. "Bayer is ...
Breaking Medicine Technology:Generex Announces Intention to Dividend a Portion of Anticipated SMFI Securities to Its Stockholders upon a Reverse Stock Split 2Generex Announces Intention to Dividend a Portion of Anticipated SMFI Securities to Its Stockholders upon a Reverse Stock Split 3Generex Announces Intention to Dividend a Portion of Anticipated SMFI Securities to Its Stockholders upon a Reverse Stock Split 4Generex Announces Intention to Dividend a Portion of Anticipated SMFI Securities to Its Stockholders upon a Reverse Stock Split 5PharmaEngine Announces Filing by Baxter BioScience of Marketing Authorization Application of MM-398 (PEP02) to the European Medicines Agency for Post-Gemcitabine Metastatic Pancreatic Cancer Patients 2PharmaEngine Announces Filing by Baxter BioScience of Marketing Authorization Application of MM-398 (PEP02) to the European Medicines Agency for Post-Gemcitabine Metastatic Pancreatic Cancer Patients 3Bayer Licenses Investigational ISIS FXI(Rx) from Isis Pharmaceuticals to Develop and Commercialize for the Prevention of Thrombosis 2Bayer Licenses Investigational ISIS FXI(Rx) from Isis Pharmaceuticals to Develop and Commercialize for the Prevention of Thrombosis 3
(Date:5/5/2015)... Seattle, WA (PRWEB) May 05, 2015 Dealing ... be a strenuous and complicated task. Personal injury lawyers are ... lawyers are created equal. In their latest article , ... individuals should search for when choosing a personal injury lawyer ... a personal injury case is a waste of time if ...
(Date:5/5/2015)... 05, 2015 The report ... provides comparative analysis on the therapeutic development ... pipelines by identifying new targets and MOAs ... report is available at http://www.rnrmarketresearch.com/liver-fibrosis-pipeline-review-h2-2014-market-report.html ... Fibrosis – Pipeline Review, H2 2014 report ...
(Date:5/5/2015)... Texting has become a common and integral part ... text as a way to communicate with patients and other ... so to assure medical records are updated after patient interaction. ... When providers transmit protected health information (PHI), or even have ... of violating the Health Insurance Portability and Accountability Act (HIPAA) ...
(Date:5/5/2015)... 2015 No one cares about health problems ... Control and Prevention cite multiple sources causing poor indoor ... indoor air quality (pollution) can bother your eyes, nose, and ... problems and cancer.” , Toxic chemicals often get into the ... or water, or in some cases, absorb them through our ...
(Date:5/4/2015)... Garden City, NY (PRWEB) May 05, 2015 ... honors Patti Hommes as a 2015-2016 ... She is recognized with this prestigious distinction for leadership ... exclusively for professional women, boasting more than 700,000 members ... to recognize Patti with this important honor,” says NAPW ...
Breaking Medicine News(10 mins):Health News:5 Top Qualifications for Personal Injury Lawyer Disclosed in Latest Article by The Jones Firm 2Health News:Liver Fibrosis Therapeutic Development and Pipeline Market Review H2 2014 Available at RnRMarketResearch.com 2Health News:Liver Fibrosis Therapeutic Development and Pipeline Market Review H2 2014 Available at RnRMarketResearch.com 3Health News:HIPAA Compliant Texting Service from MedXcom now available for Policyholders 2Health News:revitaRUGS is Offering Area Rug Cleaning Discounts in Support of Asthma and Allergy Awareness Month This May 2Health News:revitaRUGS is Offering Area Rug Cleaning Discounts in Support of Asthma and Allergy Awareness Month This May 3Health News:NAPW Inducts Patti Hommes, Director of Advancement Services, Springside Chestnut Hill Academy, a 2015-2016 Professional Woman of the Year Circle 2
... 29 The National Patient,Safety Foundation,s theme this ... the importance of improving healthcare as a joint,effort ... Supporting National Patient Safety Awareness Week, March 2-8, ... ) urges communities to,actively partner with local hospitals ...
... Cardiogenesis,Corporation (Pink Sheets: CGCP), a leading developer ... today announced that,it will delay its earnings release ... full year ended December 31, 2007. The earnings ... Tuesday, March 4,2008., The Company noted that ...
... the Only Provider to Offer Practice Management and ... of Mental Health Care Providers, GREAT RIVER, ... provider of enterprise-wide software and services for health ... Therapist,Helper product suite and operations from Nightingale VantageMed,Corporation, ...
... PRINCETON, N.J., Feb. 29 Orchid Cellmark Inc.,(Nasdaq: ... testing,services, will release its fourth quarter and full year ... 7:00 am EST, and is,hosting a conference call and ... the same day. Management will discuss financial results for ...
... heart, liver and lung transplants at UCSF Medical ... according to new data compiled by the Scientific ... Released on January 11, the report measures performance ... facilities in the United States, including waiting list ...
... and benefits still outweigh risks, experts say , , FRIDAY, ... the risk for tendon problems, French researchers report. , ... rare, considering the huge number of statin prescriptions," wrote ... March issue of Arthritis Care and Research , ...
Cached Medicine News:Health News:Encision Supports National Patient Safety Awareness Week 2Health News:Cardiogenesis Corporation Reports Delay in Earnings Release and Conference Call 2Health News:Netsmart Technologies Acquires Largest Provider of Software for Private Practice Mental Health Providers and Therapists 2Health News:Netsmart Technologies Acquires Largest Provider of Software for Private Practice Mental Health Providers and Therapists 3Health News:Netsmart Technologies Acquires Largest Provider of Software for Private Practice Mental Health Providers and Therapists 4Health News:Orchid Cellmark to Announce Fourth Quarter and Full Year 2007 Financial Results on March 6, 2008 2Health News:Survival rates exceed national averages for UCSF heart, liver and lung transplant programs 2Health News:Cholesterol-Lowering Statins Tied to Tendon Woes 2Health News:Cholesterol-Lowering Statins Tied to Tendon Woes 3
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
Medicine Products: